From sequence and structure of sulfotransferases and dihydropyrimidinases to an understanding of their mechanisms of action and function

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 5, 2010, Pages 591-601

  Hsu, Ching Chen ^a   Lu, Lu Yi ^a   Yang, Yuh Shyong ^a,b  

^a NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^b INSTRUMENT TECHNOLOGY RESEARCH CENTER   (Taiwan)

Author keywords

Dihydropyrimidinase; Polymorphism; Quaternary structure; Sulfation; Sulfotransferase

Indexed keywords

AMINO ACID; DIHYDROPYRIMIDINASE; HETERODIMER; HOMODIMER; MONOMER; SULFOTRANSFERASE;

AMINO ACID SEQUENCE; CANCER SUSCEPTIBILITY; CYTOSOL; DISEASE PREDISPOSITION; DISSOCIATION; ENZYME ANALYSIS; ENZYME BINDING; ENZYME DEFICIENCY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; GENE MUTATION; HUMAN; NONHUMAN; PREDICTION; PROTEIN ASSEMBLY; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN QUATERNARY STRUCTURE; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

AMIDOHYDROLASES; AMINO ACID SEQUENCE; CYTOSOL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, SECONDARY; SUBSTRATE SPECIFICITY; SULFOTRANSFERASES;

EID: 77951284402     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425251003601987     Document Type: Review

References (82)

1. Mulder GJ, Jakoby WB. Conjugation reactions in drug metabolism. Taylor and Francis, Ltd.; 1990
2. Zimniak P. Detoxification reactions: relevance to aging. Ageing Res Rev 2008;7:281-300
3. Guengerich FP. Cytochrome P450 and chemical toxicology. Chem Res Toxicol 2008;21:70-83
4. Iyanagi T. Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification. Int Rev Cytol 2007;260:35-112 (Pubitemid 46670211)
5. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004;431:931-945 (Pubitemid 39434409)
6. Waterston RH, Lander ES, Sulston JE. More on the sequencing of the human genome. Proc Natl Acad Sci USA 2003;100:3022-3024
7. Chandonia JM, Brenner SE. The impact of structural genomics: expectations and outcomes. Science 2006;311:347-351 (Pubitemid 43132652)
8. Marsden RL, Lewis TA, Orengo CA. Towards a comprehensive structural coverage of completed genomes: a structural genomics viewpoint. BMC Bioinformatics 2007;8:86
9. Nowell S, Falany CN. Pharmacogenetics of human cytosolic sulfotransferases. Oncogene 2006;5:1673-1678
10. Rath VL, Verdugo D, Hemmerich S. Sulfotransferase structural biology and inhibitor discovery. Drug Discov Today 2004;9:1003-1011 (Pubitemid 39574556)
11. Hemmerich S, Verdugo D, Rath VL. Strategies for drug discovery by targeting sulfation pathways. Drug Discov Today 2004;9:967-975 (Pubitemid 39469896)
12. Kauffman FC. Sulfonation in pharmacology and toxicology. Drug Metab Rev 2004;36:823-843
13. Pasqualini JR. The selective estrogen enzyme modulators in breast cancer: a review. Biochim Biophys Acta 2004;1654:123-143
14. Falany C, Roth JA. In: Human drug metabolism: from molecular biology to man. CRC Press, Inc. Boca Raton, FL; 1993
15. Weinshilboum R, Otterness D. In: Conjugation-deconjugation reactions in drug metabolism and toxicity. Springer-Verlag, Berlin, 1994
16. DeBaun JR, Miller EC, Miller JA. N-hydroxy-2-acetylaminofluorene sulfotransferase: its probable role in carcinogenesis and in protein-(methion-S-yl) binding in rat liver. Cancer Res 1970;30:577-595
17. Glatt H. Sulfation and sulfotransferases 4: bioactivation of mutagens via sulfation. FASEB J 1997;11:314-321
18. Falany CN. Sulfation and sulfotransferases. Introduction: changing view of sulfation and the cytosolic sulfotransferases. FASEB J 1997;11:1-2
19. Falany CN. Enzymology of human cytosolic sulfotransferases. FASEB J 1997;11:206-216
20. Sharma V, Duffel MW. A comparative molecular field analysis-based approach to prediction of sulfotransferase catalytic specificity. Methods Enzymol 2005;400:249-263 (Pubitemid 43052425)
21. Gamage NU, Tsvetanov S, Duggleby RG, et al. The structure of human SULT1A1 crystallized with estradiol. An insight into active site plasticity and substrate inhibition with multi-ring substrates. J Biol Chem 2005;280:41482-41486 (Pubitemid 41832208)
22. Gamage NU, Tsvetanov S, Duggleby RG, et al. Structure of a human carcinogen-converting enzyme, SULT1A1. Structural and kinetic implications of substrate inhibition. J Biol Chem 2003;278:7655-7662
23. Rehse PH, Zhou M, Lin SX. Crystal structure of human dehydroepiandrosterone sulphotransferase in complex with substrate. Biochem J 2002;364:165-171 (Pubitemid 34538959)
24. Wallach DP, Grisolia S. The purification and properties of hydropyrimidine hydrase. J Biol Chem 1957;226:277-288
25. Cai Y, Trodler P, Jiang S, et al. Isolation and molecular characterization of a novel D-hydantoinase from Jannaschia sp. CCS1. FEBS J 2009;276:3575-3588
26. Yang YS, Ramaswamy S, Jakoby WB. Rat liver imidase. J Biol Chem 1993;268:10870-10875 (Pubitemid 23162266)
27. Abendroth J, Niefind K, Schomburg D. X-ray Structure of a Dihydropyrimidinase from Thermus sp. at 1.3A - Resolution. J Mol Biol 2002;320:143-156
28. Lohkamp B, Anderson B, Piskur J, Dobritzsch D. The crystal structures of dihydropyrimidinases reaffirm the close relationship between cyclic amidohydrolases and explain their substrate specificity. J Biol Chem 2006;281:13762-13776 (Pubitemid 43855292)
29. Welin M, Karlberg T, Andersson J, et al. The crystal structure of human dihydropyrimidinase. Published on PDB 2008
30. Martínez-Rodríguez S, Martínez-Gómez AI, Clemente-Jiménez JM, et al. Structure of dihydropyrimidinase from Sinorhizobium meliloti CECT4114: new features in an amidohydrolase family member. J Struct Biol 2009; doi: 10.1016/j.jsb.2009.10.013
31. Soong CL, Ogawa J, Honda M, Shimizu S. Cyclic-imide-hydrolyzing activity of D-hydantoinase from Blastobacter sp. strain A17p-4. Appl Environ Microbiol 1999;65:1459-1462 (Pubitemid 29173671)
32. Seibert CM, Raushel FM. Structural and catalytic diversity within the amidohydrolase superfamily. Biochemistry 2005;44:6383-6391 (Pubitemid 40593789)
33. Gojkovic Z, Jahnke K, Schnackerz KD, Piskur J. PYD2 encodes 5,6-dihydropyrimidine aminohydrolase which participates in a novel fungal catabolic pathway. J Mol Biol 2000;295:1073-1087
34. Holm L, Sander C. An evolutionary treasure: unification of a broad set of amidohydrolases related to urease. Proteins 1997;28:72-82 (Pubitemid 27194020)
35. May O, Habenicht A, Mattes R, et al. Molecular evolution of hydantoinases. Biol Chem 1998;379:743-747 (Pubitemid 28327576)
36. Goshima Y, Nakamura F, Strittmatter P, Strittmatter SM. Collapsin-induced growth cone collapse mediated by an intracellular protein related to unc-33. Nature 1995;376:509-514
37. Thoden JB, Phillips GN Jr, Tamiko MN, et al. Molecular structure of dihydroorotase: a paradigm for catalysis through the use of a binuclear metal center. Biochemistry 2001;40:6989-6999
38. Jabri E, Carr MB, Hausinger RP, Karplus PA. The crystal structure of urease from Klebsiella aerogenes. Science 1995;268:998-1004
39. Deo RC, Schmidt EF, Elhabazi A, et al. Structural bases for CRMP function in plexin-dependent semaphorin3A signaling. EMBO J 2004;23:9-22 (Pubitemid 38165743)
40. Benning MM, Kuo JM, Raushel FM, Holden HM. Three-dimensional structure of phosphotriesterase: an enzyme capable of detoxifying organophosphate nerve agents. Biochemistry 1994;33:15001-15007
41. Huang CY, Yang YS. The role of metal on imide hydrolysis: metal content and pH profiles of metal ion-replaced mammalian imidase. Biochem Biophys Res Commun 2002;297:1027-1032
42. Huang CY, Hsu CC, Chen MC, Yang YS. Effect of metal binding and posttranslational lysine carboxylation on the activity of recombinant hydantoinase. J Biol Inorg Chem 2009;14:111-121
43. Duffel MW, Jakoby WB. On the mechanism of aryl sulfotransferase. J Biol Chem 1981;256:11123-11127
44. Zhang H, Varlamova O, Vargas FM, et al. Sulfuryl transfer: the catalytic mechanism of human estrogen sulfotransferase. J Biol Chem 1998;273:10888-10892 (Pubitemid 28204925)
45. Chang HJ, Shi R, Rehse P, Lin SX. Identifying androsterone (ADT) as a cognate substrate for human dehydroepiandrosterone sulfotransferase (DHEA-ST) important for steroid homeostasis: structure of the enzyme-ADT complex. J Biol Chem 2004;279:2689-2696 (Pubitemid 38114257)
46. Barnett AC, Tsvetanov S, Gamage N, et al. Active site mutations and substrate inhibition in human sulfotransferase 1A1 and 1A3. J Biol Chem 2004;279:18799-18805 (Pubitemid 38623306)
47. Lu LY, Hsieh YC, Liu MY, et al. Identification and characterization of two amino acids critical for the substrate inhibition of human dehydroepiandrosterone sulfotransferase (SULT2A1). Mol Pharmacol 2008;73:660-668
48. Pedersen LC, Petrotchenko EV, Negishi M. Crystal structure of SULT2A3, human hydroxysteroid sulfotransferase. FEBS Lett 2000;475:61-64 (Pubitemid 30331079)
49. Kuchel OG, Kuchel GA. Peripheral dopamine in pathophysiology of hypertension. Interaction with aging and lifestyle. Hypertension 1991;18:709-721
50. Goldstein DS, Swoboda KJ, Miles JM, et al. Sources and physiological significance of plasma dopamine sulfate. J Clin Endocrinol Metab 1999;84:2523-2531
51. Sakakibara Y, Katafuchi J, Takami Y, et al. Manganese-dependent Dopa/tyrosine sulfation in HepG2 human hepatoma cells: novel dopa/tyrosine sulfotransferase activities associated with the human monoamine-form phenol sulfotransferase. Biochim Biophys Acta 1997;1355:102-106 (Pubitemid 27064035)
52. Pai TG, Ohkimoto K, Sakakibara Y, et al. Manganese stimulation and stereospecificity of the Dopa (3,4-dihydroxyphenylalanine)/ tyrosine-sulfating activity of human monoamine-form phenol sulfotransferase. Kinetic studies of the mechanism using wild-type and mutant enzymes. J Biol Chem 2002;277:43813-43820 (Pubitemid 36157802)
53. Lu JH, Li HT, Liu MC, et al. Crystal structure of human sulfotransferase SULT1A3 in complex with dopamine and 3¢-phosphoadenosine 5¢-phosphate. Biochem Biophys Res Commun 2005;335:417-423
54. Lindsay J, Wang LL, Li Y, Zhou SF. Structure, function and polymorphism of human cytosolic sulfotransferases. Curr Drug Metab 2008;9:99-105 (Pubitemid 351460999)
55. Hebbring SJ, Moyer AM, Weinshilboum RM. Sulfotransferase gene copy number variation: pharmacogenetics and function. Cytogenet Genome Res 2008;123:205-210
56. Hempel N, Gamage N, Martin JL, McManus ME. Human cytosolic sulfotransferase SULT1A1. Int J Biochem Cell Biol 2007;39:685-689 (Pubitemid 46366795)
57. Hempel N, Barnett A, Gamage N, et al. Human SULT1A sulfotransferases, in Human cytosolic sulfotransferases. CRC Press, London; 2005
58. Hildebrandt MA, Salavaggione OE, Martin YN, et al. Human SULT1A3 pharmacogenetics: gene duplication and functional genomic studies. Biochem Biophys Res Commun 2004;321:870-878 (Pubitemid 39044390)
59. Blanchard RL, Freimuth RR, Buck J, et al. A proposed nomenclature system for the cytosolic sulfotransferase (SULT) superfamily. Pharmacogenetics 2004;14:199-211 (Pubitemid 38373115)
60. Hirata H, Hinoda Y, Okayama N, et al. CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer 2008;112:1964-1973 . An interesting research to corellate CYP1A1, SULT1A1 and SULT1E1 polymorphisms with endometrial cancer. (Pubitemid 351574072)
61. Nagar S, Walther S, Blanchard RL. Sulfotransferase (SULT) 1A1 polymorphic variants *1, *2, and *3 are associated with altered enzymatic activity, cellular phenotype, and protein degradation. Mol Pharmacol 2006;69:2084-2092 (Pubitemid 43894328)
62. van Kuilenburg ABP, Meinsma JR, Zonnenberg BA, et al. Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res 2003;9:4363-4367
63. van Kuilenburg ABP, Meijer J, Dobritzsch D, et al. Clinical, biochemical and genetic findings in two siblings with a dihydropyrimidinase deficiency. Mol Genet Metab 2007;91:157-164 (Pubitemid 46765171)
64. van Kuilenburg ABP. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004;40:939-950
65. Chapman E, Best MD, Hanson SR, Wong CH. Sulfotransferases: structure, mechanism, biological activity, inhibition, and synthetic utility. Angew Chem Int Ed Engl 2004;43:3526-3548
66. Strott CA. Sulfonation and molecular action. Endocr Rev 2002;23:703-732
67. Sakakibara Y, Takami Y, Nakayama T, et al. Localization and functional analysis of the substrate specificity/catalytic domains of human M-form and P-form phenol sulfotransferases. J Biol Chem 1998;273:6242-6247 (Pubitemid 28144711)
68. Liu MC, Suiko M, Sakakibara Y. Mutational analysis of the substrate binding/catalytic domains of human M form and P form phenol sulfotransferases. J Biol Chem 2000;275:13460-13464 (Pubitemid 30257410)
69. Brooks SC, Rozhin J, Pack BA, et al. Role of sulfate conjugation in estrogen metabolism and activity. J Toxicol Environ Health 1978;4:283-300 (Pubitemid 8352962)
70. Chatterjee B, Song CS, Kim JM, Roy AK. Androgen and estrogen sulfotransferases of the rat liver: physiological function, molecular cloning, and in vitro expression. Chem Biol Interact 1994;92:273-279 (Pubitemid 24220214)
71. Petrotchenko EV, Doerflein ME, Kakuta Y, et al. Substrate gating confers steroid specificity to estrogen sulfotransferase. J Biol Chem 1999;274:30019-30022 (Pubitemid 29483383)
72. Petrotchenko EV, Pedersen LC, Borchers CH, et al. The dimerization motif of cytosolic sulfotransferases. FEBS Lett 2001;490:39-43
73. Kiehlbauch CC, Lam YF, Ringer DP. Homodimeric and heterodimeric aryl sulfotransferases catalyze the sulfuric acid esterification of N-hydroxy-2-acetylaminofluorene. J Biol Chem 1995;270:18941-18947
74. Lu LY, Chiang HP, Chen WT, Yang YS. Dimerization is responsible for the structural stability of human sulfotransferase 1A1. Drug Metab Dispos 2009;37:1083-1088
75. Cheon YH, Kim HS, Han KH, et al. Crystal structure of D-hydantoinase from Bacillus stearothermophilus: insight into the stereochemistry of enantioselectivity. Biochemistry 2002;41:9410-9417 (Pubitemid 34810015)
76. Xu Z, Liu YQ, Yang YL, et al. Crystal structure of D-hydantoinase from Burkholderia pickettii at a resolution of 2.7 Angstroms: insights into the molecular basis of enzyme thermostability. J Bacteriol 2003;185:4038-4049 (Pubitemid 36835242)
77. Kim GJ, Kim HS. C-terminal regions of D-hydantoinases are non-essential for catalysis, but affect the oligomeric structure. Biochem Biophys Res Commun 1998;243:96-100
78. Niu L, Zhang X, Shi Y, Yuan J. Subunit dissociation and stability alteration of D-hydantoinase deleted at the terminal amino acid residue. Biotechnol Lett 2007;29:303-308 (Pubitemid 46089486)
79. Vakiani E, Luz JG, Buck J. Substrate specificity and kinetic mechanism of the insect sulfotransferase, retinol dehydratase. J Biol Chem 1998;273:35381-35387 (Pubitemid 29028248)
80. Pakhomova S, Kobayashi M, Buck J, Newcomer ME. A helical lid converts a sulfotransferase to a dehydratase. Nat Struct Biol 2001;8:447-451 (Pubitemid 32381294)
81. Hsiao YS, Yang YS. A single mutation converts the nucleotide specificity of phenol sulfotransferase from PAP to AMP. Biochemistry 2002;41:12959-12966
82. Cheon YH, Park HS, Kim JH, et al. Manipulation of the active site loops of D-Hydantoinase, a (alpha/beta)8-barrel protein for modulation of the substrate specificity. Biochemistry 2004;43:7413-7420